nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR3—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.00624	0.00624	CbGpPWpGaD
Ponatinib—FGFR3—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.00607	0.00607	CbGpPWpGaD
Ponatinib—FGFR3—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.00607	0.00607	CbGpPWpGaD
Ponatinib—FGFR1—FGF signaling pathway—FRS2—nasal cavity cancer	0.00596	0.00596	CbGpPWpGaD
Ponatinib—FGFR4—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00583	0.00583	CbGpPWpGaD
Ponatinib—FGFR3—PI-3K cascade—FRS2—nasal cavity cancer	0.00577	0.00577	CbGpPWpGaD
Ponatinib—FGFR3—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00564	0.00564	CbGpPWpGaD
Ponatinib—FGFR3—GAB1 signalosome—FRS2—nasal cavity cancer	0.00559	0.00559	CbGpPWpGaD
Ponatinib—FGFR4—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00558	0.00558	CbGpPWpGaD
Ponatinib—FGFR4—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00549	0.00549	CbGpPWpGaD
Ponatinib—FGFR3—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00546	0.00546	CbGpPWpGaD
Ponatinib—FGFR2—PI3K Cascade—FRS2—nasal cavity cancer	0.00532	0.00532	CbGpPWpGaD
Ponatinib—FGFR4—Downstream signal transduction—FRS2—nasal cavity cancer	0.00525	0.00525	CbGpPWpGaD
Ponatinib—FGFR4—Signaling by FGFR—FRS2—nasal cavity cancer	0.00522	0.00522	CbGpPWpGaD
Ponatinib—FGFR4—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00519	0.00519	CbGpPWpGaD
Ponatinib—FGFR4—DAP12 signaling—FRS2—nasal cavity cancer	0.00517	0.00517	CbGpPWpGaD
Ponatinib—FGFR4—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00509	0.00509	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.00504	0.00504	CbGpPWpGaD
Ponatinib—FGFR1—PI3K Cascade—FRS2—nasal cavity cancer	0.00496	0.00496	CbGpPWpGaD
Ponatinib—SRC—Signaling events regulated by Ret tyrosine kinase—FRS2—nasal cavity cancer	0.00494	0.00494	CbGpPWpGaD
Ponatinib—FGFR4—DAP12 interactions—FRS2—nasal cavity cancer	0.00486	0.00486	CbGpPWpGaD
Ponatinib—FGFR4—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00486	0.00486	CbGpPWpGaD
Ponatinib—FGFR4—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00486	0.00486	CbGpPWpGaD
Ponatinib—SRC—Negative regulation of FGFR signaling—FRS2—nasal cavity cancer	0.00484	0.00484	CbGpPWpGaD
Ponatinib—FGFR4—Signaling by EGFR—FRS2—nasal cavity cancer	0.00482	0.00482	CbGpPWpGaD
Ponatinib—FGFR4—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00478	0.00478	CbGpPWpGaD
Ponatinib—FGFR4—Signaling by PDGF—FRS2—nasal cavity cancer	0.00476	0.00476	CbGpPWpGaD
Ponatinib—ABL1—Neurotrophic factor-mediated Trk receptor signaling—FRS2—nasal cavity cancer	0.00474	0.00474	CbGpPWpGaD
Ponatinib—FGFR4—B Cell Activation—FRS2—nasal cavity cancer	0.0045	0.0045	CbGpPWpGaD
Ponatinib—SRC—Signalling to ERKs—FRS2—nasal cavity cancer	0.00448	0.00448	CbGpPWpGaD
Ponatinib—FGFR2—IRS-mediated signalling—FRS2—nasal cavity cancer	0.00445	0.00445	CbGpPWpGaD
Ponatinib—FGFR2—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00441	0.00441	CbGpPWpGaD
Ponatinib—KIT—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00433	0.00433	CbGpPWpGaD
Ponatinib—FGFR2—IRS-related events—FRS2—nasal cavity cancer	0.00433	0.00433	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00432	0.00432	CbGpPWpGaD
Ponatinib—FGFR4—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00431	0.00431	CbGpPWpGaD
Ponatinib—FGFR2—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.00429	0.00429	CbGpPWpGaD
Ponatinib—FGFR2—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.00418	0.00418	CbGpPWpGaD
Ponatinib—FGFR2—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.00418	0.00418	CbGpPWpGaD
Ponatinib—FGFR1—IRS-mediated signalling—FRS2—nasal cavity cancer	0.00415	0.00415	CbGpPWpGaD
Ponatinib—FGFR3—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00413	0.00413	CbGpPWpGaD
Ponatinib—FGFR1—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00411	0.00411	CbGpPWpGaD
Ponatinib—PDGFRA—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.0041	0.0041	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00406	0.00406	CbGpPWpGaD
Ponatinib—LCK—SHP2 signaling—FRS2—nasal cavity cancer	0.00406	0.00406	CbGpPWpGaD
Ponatinib—FGFR1—IRS-related events—FRS2—nasal cavity cancer	0.00403	0.00403	CbGpPWpGaD
Ponatinib—FGFR1—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.004	0.004	CbGpPWpGaD
Ponatinib—FGFR2—PI-3K cascade—FRS2—nasal cavity cancer	0.00397	0.00397	CbGpPWpGaD
Ponatinib—KIT—PI-3K cascade—FRS2—nasal cavity cancer	0.0039	0.0039	CbGpPWpGaD
Ponatinib—FGFR1—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.00389	0.00389	CbGpPWpGaD
Ponatinib—FGFR1—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.00389	0.00389	CbGpPWpGaD
Ponatinib—FGFR3—Downstream signal transduction—FRS2—nasal cavity cancer	0.00388	0.00388	CbGpPWpGaD
Ponatinib—FGFR2—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00388	0.00388	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by FGFR—FRS2—nasal cavity cancer	0.00386	0.00386	CbGpPWpGaD
Ponatinib—FGFR2—GAB1 signalosome—FRS2—nasal cavity cancer	0.00385	0.00385	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00384	0.00384	CbGpPWpGaD
Ponatinib—FGFR3—DAP12 signaling—FRS2—nasal cavity cancer	0.00382	0.00382	CbGpPWpGaD
Ponatinib—KIT—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00381	0.00381	CbGpPWpGaD
Ponatinib—SRC—FGF signaling pathway—FRS2—nasal cavity cancer	0.00381	0.00381	CbGpPWpGaD
Ponatinib—KIT—GAB1 signalosome—FRS2—nasal cavity cancer	0.00378	0.00378	CbGpPWpGaD
Ponatinib—FGFR3—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00377	0.00377	CbGpPWpGaD
Ponatinib—FGFR2—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00376	0.00376	CbGpPWpGaD
Ponatinib—FGFR1—PI-3K cascade—FRS2—nasal cavity cancer	0.0037	0.0037	CbGpPWpGaD
Ponatinib—PDGFRA—PI-3K cascade—FRS2—nasal cavity cancer	0.00369	0.00369	CbGpPWpGaD
Ponatinib—KIT—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00369	0.00369	CbGpPWpGaD
Ponatinib—FGFR1—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00361	0.00361	CbGpPWpGaD
Ponatinib—PDGFRA—PI3K/AKT activation—FRS2—nasal cavity cancer	0.0036	0.0036	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0036	0.0036	CbGpPWpGaD
Ponatinib—FGFR3—DAP12 interactions—FRS2—nasal cavity cancer	0.0036	0.0036	CbGpPWpGaD
Ponatinib—FGFR3—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0036	0.0036	CbGpPWpGaD
Ponatinib—FGFR1—GAB1 signalosome—FRS2—nasal cavity cancer	0.00358	0.00358	CbGpPWpGaD
Ponatinib—PDGFRA—GAB1 signalosome—FRS2—nasal cavity cancer	0.00357	0.00357	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by EGFR—FRS2—nasal cavity cancer	0.00357	0.00357	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00353	0.00353	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by PDGF—FRS2—nasal cavity cancer	0.00352	0.00352	CbGpPWpGaD
Ponatinib—FGFR1—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.0035	0.0035	CbGpPWpGaD
Ponatinib—PDGFRA—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00349	0.00349	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.00347	0.00347	CbGpPWpGaD
Ponatinib—FGFR3—B Cell Activation—FRS2—nasal cavity cancer	0.00333	0.00333	CbGpPWpGaD
Ponatinib—FGFR4—Signaling by NGF—FRS2—nasal cavity cancer	0.00331	0.00331	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.00323	0.00323	CbGpPWpGaD
Ponatinib—FGFR3—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00319	0.00319	CbGpPWpGaD
Ponatinib—LYN—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00308	0.00308	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00297	0.00297	CbGpPWpGaD
Ponatinib—LCK—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00296	0.00296	CbGpPWpGaD
Ponatinib—KIT—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00291	0.00291	CbGpPWpGaD
Ponatinib—FGFR2—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00284	0.00284	CbGpPWpGaD
Ponatinib—ABCB1—Allograft Rejection—CXCL11—nasal cavity cancer	0.00282	0.00282	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00279	0.00279	CbGpPWpGaD
Ponatinib—KIT—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00279	0.00279	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00277	0.00277	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00276	0.00276	CbGpPWpGaD
Ponatinib—KIT—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00274	0.00274	CbGpPWpGaD
Ponatinib—FGFR2—Downstream signal transduction—FRS2—nasal cavity cancer	0.00267	0.00267	CbGpPWpGaD
Ponatinib—LCK—PI-3K cascade—FRS2—nasal cavity cancer	0.00267	0.00267	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by FGFR—FRS2—nasal cavity cancer	0.00266	0.00266	CbGpPWpGaD
Ponatinib—FGFR1—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00265	0.00265	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00264	0.00264	CbGpPWpGaD
Ponatinib—PDGFRA—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00264	0.00264	CbGpPWpGaD
Ponatinib—FGFR2—DAP12 signaling—FRS2—nasal cavity cancer	0.00263	0.00263	CbGpPWpGaD
Ponatinib—KIT—Downstream signal transduction—FRS2—nasal cavity cancer	0.00262	0.00262	CbGpPWpGaD
Ponatinib—KIT—Signaling by FGFR—FRS2—nasal cavity cancer	0.00261	0.00261	CbGpPWpGaD
Ponatinib—LCK—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00261	0.00261	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0026	0.0026	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0026	0.0026	CbGpPWpGaD
Ponatinib—KIT—Signaling by ERBB2—FRS2—nasal cavity cancer	0.0026	0.0026	CbGpPWpGaD
Ponatinib—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00259	0.00259	CbGpPWpGaD
Ponatinib—LCK—GAB1 signalosome—FRS2—nasal cavity cancer	0.00258	0.00258	CbGpPWpGaD
Ponatinib—KIT—DAP12 signaling—FRS2—nasal cavity cancer	0.00258	0.00258	CbGpPWpGaD
Ponatinib—KIT—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00255	0.00255	CbGpPWpGaD
Ponatinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00253	0.00253	CbGpPWpGaD
Ponatinib—FGFR1—Downstream signal transduction—FRS2—nasal cavity cancer	0.00249	0.00249	CbGpPWpGaD
Ponatinib—PDGFRA—Downstream signal transduction—FRS2—nasal cavity cancer	0.00248	0.00248	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by FGFR—FRS2—nasal cavity cancer	0.00248	0.00248	CbGpPWpGaD
Ponatinib—FGFR2—DAP12 interactions—FRS2—nasal cavity cancer	0.00247	0.00247	CbGpPWpGaD
Ponatinib—FGFR2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00247	0.00247	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00247	0.00247	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by FGFR—FRS2—nasal cavity cancer	0.00247	0.00247	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00246	0.00246	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00246	0.00246	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by EGFR—FRS2—nasal cavity cancer	0.00245	0.00245	CbGpPWpGaD
Ponatinib—FGFR1—DAP12 signaling—FRS2—nasal cavity cancer	0.00245	0.00245	CbGpPWpGaD
Ponatinib—FGFR3—Signaling by NGF—FRS2—nasal cavity cancer	0.00245	0.00245	CbGpPWpGaD
Ponatinib—PDGFRA—DAP12 signaling—FRS2—nasal cavity cancer	0.00244	0.00244	CbGpPWpGaD
Ponatinib—LYN—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00243	0.00243	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00243	0.00243	CbGpPWpGaD
Ponatinib—KIT—DAP12 interactions—FRS2—nasal cavity cancer	0.00243	0.00243	CbGpPWpGaD
Ponatinib—KIT—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00243	0.00243	CbGpPWpGaD
Ponatinib—KIT—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00243	0.00243	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by PDGF—FRS2—nasal cavity cancer	0.00242	0.00242	CbGpPWpGaD
Ponatinib—FGFR1—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00242	0.00242	CbGpPWpGaD
Ponatinib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00241	0.00241	CbGpPWpGaD
Ponatinib—KIT—Signaling by EGFR—FRS2—nasal cavity cancer	0.00241	0.00241	CbGpPWpGaD
Ponatinib—KIT—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00239	0.00239	CbGpPWpGaD
Ponatinib—KIT—Signaling by PDGF—FRS2—nasal cavity cancer	0.00238	0.00238	CbGpPWpGaD
Ponatinib—FGFR1—DAP12 interactions—FRS2—nasal cavity cancer	0.00231	0.00231	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00231	0.00231	CbGpPWpGaD
Ponatinib—FGFR1—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00231	0.00231	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0023	0.0023	CbGpPWpGaD
Ponatinib—PDGFRA—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0023	0.0023	CbGpPWpGaD
Ponatinib—PDGFRA—DAP12 interactions—FRS2—nasal cavity cancer	0.0023	0.0023	CbGpPWpGaD
Ponatinib—FGFR2—B Cell Activation—FRS2—nasal cavity cancer	0.00229	0.00229	CbGpPWpGaD
Ponatinib—SRC—GAB1 signalosome—FRS2—nasal cavity cancer	0.00229	0.00229	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by EGFR—FRS2—nasal cavity cancer	0.00229	0.00229	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by EGFR—FRS2—nasal cavity cancer	0.00228	0.00228	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00227	0.00227	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00226	0.00226	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by PDGF—FRS2—nasal cavity cancer	0.00226	0.00226	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by PDGF—FRS2—nasal cavity cancer	0.00225	0.00225	CbGpPWpGaD
Ponatinib—KIT—B Cell Activation—FRS2—nasal cavity cancer	0.00225	0.00225	CbGpPWpGaD
Ponatinib—FGFR2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00219	0.00219	CbGpPWpGaD
Ponatinib—KIT—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00215	0.00215	CbGpPWpGaD
Ponatinib—FGFR1—B Cell Activation—FRS2—nasal cavity cancer	0.00213	0.00213	CbGpPWpGaD
Ponatinib—PDGFRA—B Cell Activation—FRS2—nasal cavity cancer	0.00213	0.00213	CbGpPWpGaD
Ponatinib—FGFR1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00204	0.00204	CbGpPWpGaD
Ponatinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00204	0.00204	CbGpPWpGaD
Ponatinib—LYN—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00203	0.00203	CbGpPWpGaD
Ponatinib—LCK—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00199	0.00199	CbGpPWpGaD
Ponatinib—LCK—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00191	0.00191	CbGpPWpGaD
Ponatinib—FGFR4—Innate Immune System—FRS2—nasal cavity cancer	0.00189	0.00189	CbGpPWpGaD
Ponatinib—LCK—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00188	0.00188	CbGpPWpGaD
Ponatinib—LYN—B Cell Activation—FRS2—nasal cavity cancer	0.00188	0.00188	CbGpPWpGaD
Ponatinib—FGFR4—Adaptive Immune System—FRS2—nasal cavity cancer	0.00181	0.00181	CbGpPWpGaD
Ponatinib—LCK—Downstream signal transduction—FRS2—nasal cavity cancer	0.00179	0.00179	CbGpPWpGaD
Ponatinib—LCK—Signaling by FGFR—FRS2—nasal cavity cancer	0.00179	0.00179	CbGpPWpGaD
Ponatinib—LCK—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00178	0.00178	CbGpPWpGaD
Ponatinib—LCK—DAP12 signaling—FRS2—nasal cavity cancer	0.00177	0.00177	CbGpPWpGaD
Ponatinib—SRC—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00177	0.00177	CbGpPWpGaD
Ponatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00174	0.00174	CbGpPWpGaD
Ponatinib—SRC—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00174	0.00174	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—CXCL11—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by NGF—FRS2—nasal cavity cancer	0.00169	0.00169	CbGpPWpGaD
Ponatinib—LCK—DAP12 interactions—FRS2—nasal cavity cancer	0.00166	0.00166	CbGpPWpGaD
Ponatinib—LCK—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00166	0.00166	CbGpPWpGaD
Ponatinib—LCK—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00166	0.00166	CbGpPWpGaD
Ponatinib—KIT—Signaling by NGF—FRS2—nasal cavity cancer	0.00166	0.00166	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR—FRS2—nasal cavity cancer	0.00165	0.00165	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00163	0.00163	CbGpPWpGaD
Ponatinib—LCK—Signaling by PDGF—FRS2—nasal cavity cancer	0.00163	0.00163	CbGpPWpGaD
Ponatinib—SRC—Downstream signal transduction—FRS2—nasal cavity cancer	0.00159	0.00159	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR—FRS2—nasal cavity cancer	0.00158	0.00158	CbGpPWpGaD
Ponatinib—SRC—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00157	0.00157	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by NGF—FRS2—nasal cavity cancer	0.00157	0.00157	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by NGF—FRS2—nasal cavity cancer	0.00157	0.00157	CbGpPWpGaD
Ponatinib—LCK—B Cell Activation—FRS2—nasal cavity cancer	0.00154	0.00154	CbGpPWpGaD
Ponatinib—LCK—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00147	0.00147	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00147	0.00147	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR—FRS2—nasal cavity cancer	0.00146	0.00146	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00145	0.00145	CbGpPWpGaD
Ponatinib—BCR—Disease—FRS2—nasal cavity cancer	0.00144	0.00144	CbGpPWpGaD
Ponatinib—SRC—Signaling by PDGF—FRS2—nasal cavity cancer	0.00144	0.00144	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—FRS2—nasal cavity cancer	0.0014	0.0014	CbGpPWpGaD
Ponatinib—FGFR3—Adaptive Immune System—FRS2—nasal cavity cancer	0.00134	0.00134	CbGpPWpGaD
Ponatinib—SRC—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00121	0.00121	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—FRS2—nasal cavity cancer	0.00113	0.00113	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—FRS2—nasal cavity cancer	0.0011	0.0011	CbGpPWpGaD
Ponatinib—FGFR4—Disease—FRS2—nasal cavity cancer	0.00102	0.00102	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—FRS2—nasal cavity cancer	0.00101	0.00101	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—FRS2—nasal cavity cancer	0.001	0.001	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—FRS2—nasal cavity cancer	0.000961	0.000961	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—FRS2—nasal cavity cancer	0.000944	0.000944	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—FRS2—nasal cavity cancer	0.000923	0.000923	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—FRS2—nasal cavity cancer	0.000907	0.000907	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—FRS2—nasal cavity cancer	0.000896	0.000896	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—FRS2—nasal cavity cancer	0.000894	0.000894	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CXCL11—nasal cavity cancer	0.000893	0.000893	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—FRS2—nasal cavity cancer	0.00086	0.00086	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—FRS2—nasal cavity cancer	0.000858	0.000858	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—FRS2—nasal cavity cancer	0.000814	0.000814	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—FRS2—nasal cavity cancer	0.000788	0.000788	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—FRS2—nasal cavity cancer	0.000785	0.000785	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CXCL11—nasal cavity cancer	0.000778	0.000778	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—FRS2—nasal cavity cancer	0.000757	0.000757	CbGpPWpGaD
Ponatinib—FGFR3—Disease—FRS2—nasal cavity cancer	0.000752	0.000752	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—FRS2—nasal cavity cancer	0.000712	0.000712	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—FRS2—nasal cavity cancer	0.000646	0.000646	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00062	0.00062	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CXCL11—nasal cavity cancer	0.000614	0.000614	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CXCL11—nasal cavity cancer	0.000603	0.000603	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000572	0.000572	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—FRS2—nasal cavity cancer	0.000572	0.000572	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CXCL11—nasal cavity cancer	0.000571	0.000571	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—FRS2—nasal cavity cancer	0.00056	0.00056	CbGpPWpGaD
Ponatinib—KIT—Immune System—FRS2—nasal cavity cancer	0.00055	0.00055	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—FRS2—nasal cavity cancer	0.000549	0.000549	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—FRS2—nasal cavity cancer	0.000526	0.000526	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—FRS2—nasal cavity cancer	0.000522	0.000522	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—FRS2—nasal cavity cancer	0.000521	0.000521	CbGpPWpGaD
Ponatinib—FGFR2—Disease—FRS2—nasal cavity cancer	0.000517	0.000517	CbGpPWpGaD
Ponatinib—KIT—Disease—FRS2—nasal cavity cancer	0.000508	0.000508	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL11—nasal cavity cancer	0.000504	0.000504	CbGpPWpGaD
Ponatinib—FGFR1—Disease—FRS2—nasal cavity cancer	0.000482	0.000482	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—FRS2—nasal cavity cancer	0.000481	0.000481	CbGpPWpGaD
Ponatinib—LYN—Immune System—FRS2—nasal cavity cancer	0.000459	0.000459	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—FRS2—nasal cavity cancer	0.000459	0.000459	CbGpPWpGaD
Ponatinib—ABL1—Immune System—FRS2—nasal cavity cancer	0.000457	0.000457	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL11—nasal cavity cancer	0.000413	0.000413	CbGpPWpGaD
Ponatinib—LCK—Immune System—FRS2—nasal cavity cancer	0.000376	0.000376	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL11—nasal cavity cancer	0.000365	0.000365	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—FRS2—nasal cavity cancer	0.000362	0.000362	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—FRS2—nasal cavity cancer	0.000356	0.000356	CbGpPWpGaD
Ponatinib—LCK—Disease—FRS2—nasal cavity cancer	0.000347	0.000347	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—FRS2—nasal cavity cancer	0.000337	0.000337	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—FRS2—nasal cavity cancer	0.000337	0.000337	CbGpPWpGaD
Ponatinib—SRC—Immune System—FRS2—nasal cavity cancer	0.000333	0.000333	CbGpPWpGaD
Ponatinib—SRC—Disease—FRS2—nasal cavity cancer	0.000308	0.000308	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—FRS2—nasal cavity cancer	0.000297	0.000297	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FRS2—nasal cavity cancer	0.000243	0.000243	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FRS2—nasal cavity cancer	0.000215	0.000215	CbGpPWpGaD
